Merus(US:MRUS) Globenewswireยท2025-10-13 16:00Core Insights - Merus N.V. announced the acceptance of two abstracts on petosemtamab for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from October 22-26, 2025 [1][2] Company Overview - Merus is an oncology company focused on developing innovative full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics, which exhibit features similar to conventional human monoclonal antibodies [5] Product Information - Petosemtamab, also known as MCLA-158, is a Biclonics low-fucose human full-length IgG1 antibody targeting EGFR and LGR5, designed to inhibit EGFR-dependent signaling and enhance antibody-dependent cell-mediated cytotoxicity [4] Presentation Details - Initial interim data from a phase 2 trial evaluating petosemtamab in combination with standard chemotherapy for metastatic colorectal cancer will be presented in a plenary session on October 24, 2025 [2][3] - A poster presentation on the preclinical evaluation of petosemtamab on cancer stem cells will also take place on the same day [2][3]